Rafael Holdings, Inc. (RFL)

Rafael Holdings, Inc. (RFL) Real Estate Portfolio & Strategy

Rafael Holdings, Inc. is a diversified entity operating in both pharmaceutical development and commercial real estate. The company focuses on advancing lead drug candidate CPI-613 for oncology while managing a portfolio of commercial properties and an associated parking garage in the US and Israel, positioning it uniquely across two distinct sectors.

What Is the Investment Thesis for RFL?

Rafael Holdings, Inc. presents an investment thesis centered on the high-potential, binary outcomes of its lead pharmaceutical asset, CPI-613, balanced by its foundational commercial real estate holdings. The primary value driver is the advancement of CPI-613 through two ongoing Phase III registrational clinical trials for metastatic pancreatic cancer and r/r acute myeloid leukemia. Positive results from these trials, which could lead to regulatory approval, represent a significant catalyst with the potential for substantial value creation, given the unmet medical needs in these oncology indications. The company's current market capitalization of $115.76M and a high gross margin of 93.1% highlight the potential leverage if CPI-613 succeeds commercially. Conversely, the real estate segment, comprising a commercial office building and an 800-car public garage, provides a tangible asset base and recurring revenue streams, offering some diversification from the inherent risks of drug development. However, the company's negative Return on Equity (ROE) of -41.4% and a Debt-to-Equity (D/E) ratio of 0.79 indicate financial challenges, potentially linked to significant R&D expenditures. The low Beta of 0.49 suggests lower volatility relative to the market. Investors evaluating RFL must weigh the substantial upside potential from successful drug development against the significant clinical and commercialization risks, alongside the performance of its real estate portfolio.

Based on FMP financials and quantitative analysis

RFL Key Highlights

• Market Capitalization of $115.76M, reflecting its status as a small-cap company with potentially high growth leverage.
• Gross Margin of 93.1%, indicating strong profitability on its revenue, likely driven by its real estate leasing activities.
• Return on Equity (ROE) of -41.4%, signaling unprofitability and challenges in generating returns for shareholders.
• Debt-to-Equity (D/E) ratio of 0.79, suggesting a moderate level of financial leverage compared to its equity.
• Beta of 0.49, indicating lower volatility and sensitivity to overall market movements compared to the broader market.

Who Are RFL's Competitors?

RFL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RFL's Key Strengths?

• Lead drug candidate CPI-613 in two Phase III registrational trials for significant oncology indications.
• Diversified business model with both pharmaceutical development and commercial real estate assets.
• High gross margin of 93.1%, indicative of efficient revenue generation from existing assets.
• Strategic real estate holdings in the US and Israel providing stable, recurring revenue.

What Are RFL's Weaknesses?

• Negative Return on Equity (-41.4%) indicating current unprofitability and challenges in generating shareholder returns.
• Small market capitalization ($0.05B) and limited employee base (28) may constrain large-scale operations.
• Significant reliance on the successful outcome of CPI-613 clinical trials, which carry inherent high risk.
• Dual-segment business model may lead to complexity in management and investor perception.

What Could Drive RFL Stock Higher?

• Announcement of top-line data from the Phase III registrational clinical trial for CPI-613 in metastatic pancreatic cancer, expected to significantly impact the company's valuation.
• Release of results from the Phase III registrational clinical trial for CPI-613 in relapsed/refractory acute myeloid leukemia, which could open another major market opportunity.
• Strategic initiatives to optimize occupancy rates and rental income from its commercial office building and 800-car public garage, enhancing the stability of its real estate segment.

What Are the Key Risks for RFL?

• Financial-distress signal — its Altman Z-Score of 1.56 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-39.0%) — the business is not currently generating profit on shareholder capital.
• Clinical trial failure of CPI-613 in either the metastatic pancreatic cancer or r/r acute myeloid leukemia Phase III trials, which would significantly impair the company's pharmaceutical segment value.
• High cash burn associated with pharmaceutical R&D, potentially leading to future capital raises and shareholder dilution given the negative Return on Equity of -41.4%.
• Adverse market conditions in the commercial real estate sector, such as increased vacancies or declining property values, impacting the stability and revenue of its real estate assets.
• Regulatory hurdles and delays in the drug approval process, even if clinical trials are successful, could postpone market entry and revenue generation for CPI-613.

What Are the Growth Opportunities for RFL?

• Growth opportunity 1: Successful Clinical Development and Commercialization of CPI-613 for Metastatic Pancreatic Cancer. The global market for pancreatic cancer therapeutics is projected to reach several billion dollars in the coming years, driven by increasing incidence and the need for more effective treatments. With CPI-613 currently in a Phase III registrational trial, a positive outcome could unlock access to a significant patient population and establish a new standard of care. This represents a major growth catalyst, potentially transforming the company's revenue profile and market valuation over a 2-5 year timeline, contingent on trial success and regulatory approval.
• Growth opportunity 2: Advancement and Approval of CPI-613 for Relapsed/Refractory Acute Myeloid Leukemia (r/r AML). The market for AML treatments, particularly for relapsed or refractory cases, also represents a substantial unmet medical need and a multi-billion dollar opportunity. CPI-613's ongoing Phase III trial in this indication positions Rafael Holdings to potentially address a critical patient population with limited effective options. Success in this trial and subsequent market entry would provide a second significant revenue stream, diversifying the company's pharmaceutical portfolio and accelerating growth within a 2-5 year horizon, subject to clinical and regulatory milestones.
• Growth opportunity 3: Optimization and Potential Expansion of Commercial Real Estate Portfolio. Rafael Holdings' existing commercial office building and 800-car public garage in the US and Israel provide a stable asset base. Opportunities exist to enhance revenue through strategic leasing initiatives, property upgrades, or potential acquisitions of additional income-generating properties in attractive markets. While specific market sizes for its current assets are not provided, the broader commercial real estate market continues to evolve, offering avenues for growth through prudent management and targeted expansion. This offers a more stable, incremental growth path over a continuous timeline.
• Growth opportunity 4: Strategic Investments in Early-Stage Pharmaceutical Assets. Beyond CPI-613, Rafael Holdings holds interests in other early-stage pharmaceutical companies. This provides a pipeline of potential future drug candidates and diversification within its pharmaceutical segment. Identifying and nurturing promising early-stage assets, potentially leveraging its expertise in metabolic oncology, could lead to the development of new therapies and future revenue streams. This long-term growth driver, spanning 5-10+ years, mitigates the single-asset risk associated with CPI-613 and positions the company for sustained innovation.
• Growth opportunity 5: Leveraging the Metabolic Targeting Platform for Broader Oncology Applications. CPI-613's mechanism of action, which exploits the metabolic differences between normal and cancer cells, represents a novel approach to oncology. This platform technology could potentially be applied to other cancer types beyond pancreatic cancer and AML, or even to other diseases where metabolic dysregulation plays a key role. Further research and development into new indications or drug candidates based on this metabolic targeting strategy could unlock significant long-term growth opportunities, potentially expanding the company's therapeutic reach over a 5-10 year timeframe.

What Opportunities Does RFL Have?

• Successful regulatory approval and commercialization of CPI-613 for pancreatic cancer and AML.
• Expansion of its real estate portfolio through strategic acquisitions or development in key markets.
• Potential for licensing agreements or partnerships for CPI-613 or other early-stage assets.
• Exploration of additional indications for CPI-613 or development of new drugs based on its metabolic targeting approach.

What Threats Does RFL Face?

• Failure of CPI-613 in ongoing Phase III clinical trials or inability to secure regulatory approval.
• Intense competition in both the oncology drug development and commercial real estate markets.
• Adverse changes in real estate market conditions, such as declining occupancy rates or property values.
• Significant capital requirements for drug development, potentially leading to further dilution or debt.

What Are RFL's Competitive Advantages?

• Proprietary drug candidate CPI-613 with a unique mechanism of action targeting cancer cell metabolism.
• Ongoing Phase III clinical trials for CPI-613, representing significant investment and progress towards market entry.
• Diversified asset base combining high-potential pharmaceutical R&D with stable commercial real estate income.
• Strategic real estate holdings in established markets (US and Israel) providing recurring revenue streams.

What Does RFL Do?

Rafael Holdings, Inc. is a unique entity that strategically operates across two distinct and seemingly disparate segments: Pharmaceuticals and Real Estate. Headquartered in Newark, New Jersey, the company was established to hold interests in both clinical and early-stage pharmaceutical companies, alongside a portfolio of commercial real estate assets located in the United States and Israel. This dual-segment approach provides a diversified operational framework, though each segment operates with its own specific objectives and market dynamics. In its Pharmaceuticals segment, Rafael Holdings is dedicated to the development and commercialization of novel therapies, particularly those that exploit the metabolic differences inherent between normal cells and cancer cells. The cornerstone of this segment is its lead drug candidate, CPI-613, also known as devimistat. This investigational drug is currently undergoing rigorous evaluation in multiple clinical studies, including two pivotal Phase III registrational clinical trials. These trials are specifically targeting the treatment of metastatic pancreatic cancer and relapsed/refractory acute myeloid leukemia (r/r AML), representing significant unmet medical needs within oncology. The company's commitment in this area underscores its potential to contribute to advanced cancer treatment options. Complementing its pharmaceutical endeavors, the Real Estate segment of Rafael Holdings is engaged in the leasing of a commercial office building. This asset is further enhanced by an associated 800-car public garage, providing a steady stream of revenue and contributing to the company's overall financial stability. The strategic location of these real estate assets in the United States and Israel allows Rafael Holdings to tap into established property markets, offering a tangible asset base that contrasts with the long-term, high-risk, high-reward nature of drug development. The company's operational structure, with a lean team of 28 employees, reflects its focus on managing these distinct yet interconnected business lines.

What Products and Services Does RFL Offer?

• Develop and commercialize therapies that target metabolic differences in cancer cells.
• Conduct clinical trials for lead drug candidate CPI-613 (devimistat) in oncology.
• Lease commercial office space in the United States.
• Operate an 800-car public garage associated with its commercial real estate.
• Hold interests in various clinical and early-stage pharmaceutical companies.
• Manage commercial real estate assets in both the United States and Israel.

How Does RFL Make Money?

• Generate revenue from leasing commercial office space and operating a public parking garage.
• Invest in and develop pharmaceutical assets with the goal of commercializing new drug therapies.
• Seek regulatory approval for lead drug candidate CPI-613 to enter the market for oncology treatments.
• Potentially license or partner with larger pharmaceutical companies for drug development and commercialization.

What Industry Does RFL Operate In?

Rafael Holdings, Inc. operates within a unique intersection of the Real Estate and Pharmaceutical sectors, positioning it distinctly within the broader market. In the Real Estate sector, specifically Real Estate - Services, the company engages in commercial property leasing, including an office building and a public garage. This segment operates within a mature market influenced by economic cycles, interest rates, and regional demand for commercial space. While specific market trends for its niche are not provided, the general commercial real estate market has seen shifts in demand due to evolving work patterns, though essential services and stable assets like parking garages can offer resilience. The competitive landscape includes numerous local and regional property owners and management firms. Concurrently, its Pharmaceuticals segment places it within the highly competitive and capital-intensive biotechnology and pharmaceutical industry. This segment focuses on oncology drug development, a market characterized by significant R&D investment, long development timelines, and high regulatory hurdles. The global oncology market is projected for substantial growth, driven by an aging population and advancements in treatment modalities. Rafael Holdings competes with established pharmaceutical giants and numerous smaller biotech firms, all vying for market share in specific cancer indications. Its strategy hinges on the differentiation and clinical success of its lead candidate, CPI-613, in exploiting metabolic differences in cancer cells.

Who Are RFL's Key Customers?

• Tenants of its commercial office building.
• Individuals and businesses utilizing its 800-car public garage.
• Future patients suffering from metastatic pancreatic cancer, pending drug approval.
• Future patients suffering from relapsed/refractory acute myeloid leukemia, pending drug approval.
• Potential pharmaceutical partners for co-development or licensing agreements.

Company Profile

Rafael Holdings, Inc. operates in the Real Estate - Services industry within the Real Estate sector. It is headquartered in Newark, US. The company is led by CEO Howard S. Jonas. RFL has traded publicly since 2018.

How Rafael Holdings, Inc. Is Valued

Rafael Holdings, Inc. carries a market capitalization of $115.76M, placing it in the micro-cap category. Relative to its peer group, RFL's quantitative score of 23/100 is below the peer average of 63/100.

ROE -39%Key Financial Metrics

Return on equity for Rafael Holdings, Inc. stands at -39.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -24.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Rafael Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.56 places it in the distress zone, a signal of elevated financial risk.

RFL Financials

RFL Latest News

RFL Analyst Consensus

RFL MoonshotScore

Common Questions About RFL (Real Estate)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources